Immune Checkpoint Inhibitors: all 7,814 studies that test it
Page 24 of 79. Open to participants first (2,629), then studies with results posted, then the rest; newest registration first within each.
- A Phase Ia Clinical Study of QLF31907 Injection in Patients With Advanced Malignant TumorsRecruitingNCT05150405Phase 1
- Toripalimab Combined With Radiotherapy in the Treatment of Oligometastatic Nasopharyngeal CarcinomaRecruitingNCT05147844Phase 2
- A Study of AK109 Combined With AK104 in Patients With Advanced Solid TumorsRecruitingNCT05142423Phase 1/2
- BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot StudyRecruitingNCT05136196Phase 2
- Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic CancerRecruitingNCT05132504Phase 2
- Chemo-immunotherapy, Hypo-fractionated RT and Maintenance Immunotherapy for Stage III NSCLC.RecruitingNCT05128630Phase 2
- Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCCRecruitingNCT05125055Phase 2/3
- A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid MalignanciesRecruitingNCT05123482Phase 1/2
- First in Human Study of T3P-Y058-739 (T3P)RecruitingNCT05120596Phase 1/2
- Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial CancerRecruitingNCT05112991Phase 2
- Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial CarcinomaRecruitingNCT05112601Phase 2
- Intrathecal Application of PD1 Antibody in Metastatic Solid Tumors With Leptomeningeal Disease (IT-PD1/ NOA 26)RecruitingNCT05112549Phase 1
- Cryoablation Combined with Sintilimab Plus Lenvatinib in Previously Treated Unresectable Liver Metastasis from Solid TumorsRecruitingNCT05098847Phase 2
- Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung CancerRecruitingNCT05098210Phase 1
- Neoadjuvant Sintilimab Combined With Reduction of Cycles of Chemotherapy in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma (OOC-002)RecruitingNCT05098119Phase 2
- Camrelizumab for the Treatment of Locally Advanced Nasopharyngeal CarcinomaRecruitingNCT05097209Phase 2
- Atezolizumab+Bevacizumab+SBRT in Unresectable HCCRecruitingNCT05096715Phase 1
- Axitinib +/- Pembrolizumab in First Line Treatment of mPRCCRecruitingNCT05096390Phase 2
- Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic CancerRecruitingNCT05093231Phase 2
- Maintenance Ipilimumab + Nivolumab Post Induction Chemotherapy + SBRT for First Line Treatment Stage IV Pancreatic CancerRecruitingNCT05088889Phase 1
- Radiotherapy in Combination With Atezolizumab in Locally Advanced Borderline Resectable or Unresectable Cutaneous SCCRecruitingNCT05085496Phase 1
- A Randomised Open-label Phase III Trial of REduced Frequency Pembrolizumab immuNothErapy for First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)RecruitingNCT05085028Phase 3
- Carmustine Wafer in Combination With Retifanlimab and Radiation With/Without Temozolomide in Subjects With GlioblastomaRecruitingNCT05083754Phase 1
- Reverse Triple Negative Immune Resistant Breast CancerRecruitingNCT05076682Phase 2
- Pembrolizumab Monotherapy Following Tri-modality Treatment for Selected Patients With Muscle-invasive Bladder CancerRecruitingNCT05072600Phase 2
- Neoadjuvant Personalized Anti-PD-1 and Anti-VEGFR Therapy in OSCC PatientsRecruitingNCT05069857Phase 2
- Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)RecruitingNCT05068232Phase 2
- Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitorRecruitingNCT05065021Phase 2
- Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain MetastasesRecruitingNCT05064280Phase 2
- Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung CancerRecruitingNCT05061550Phase 2
- Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the LungRecruitingNCT05058651Phase 2/3
- Cryoablation Combined with Tislelizumab Plus Lenvatinib As Second-line or Later Therapy in Advanced Hepatocellular CarcinomaRecruitingNCT05057845Phase 2
- Cryoablation Combined with Sintilimab Plus Regorafenib in Previously Treated Colorectal Cancer Liver MetastasisRecruitingNCT05057052Phase 2
- Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint InhibitorsRecruitingNCT05055908Phase 3
- Efficiency and Safety of Microwave Ablation Plus Immune Checkpoint Inhibitor for Patients With Multiple Primary Lung Cancer: A Open, Multi-center, Phase II Clinical TrialRecruitingNCT05053802Phase 2
- A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain MetastasesRecruitingNCT05048212Phase 2
- Regorafenib Combined With PD-1 Inhibitor Therapy for Second-line Treatment of Hepatocellular CarcinomaRecruitingNCT05048017Phase 2
- Alpha Radiation Emitters Device (DaRT) in Combination With Check Point Inhibitor for the Treatment of Recurrent Unresectable or mHNSCCRecruitingNCT05047094Not applicable
- A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung CancerRecruitingNCT05042375Phase 3
- Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated With Brentuximab Vedotin or Checkpoint InhibitorsRecruitingNCT05039073Phase 2
- PD-1 Blockade With JS001 Plus Neoadjuvant Chemotherapy for Gastric/Gastroesophageal Junction CancerRecruitingNCT05033392Phase 2
- Hyperbaric Oxygen Therapy Combined Camrelizumab in Patients With Advanced/Metastatic Hepatocellular CarcinomaRecruitingNCT05031949Phase 1
- A Phase II Study of Anlotinib Combined With Penpulimab in Subjects With Gynecological CancerRecruitingNCT05028504Phase 2
- Immunotherapy With Chemotherapy and Chemoradiation for Advanced Squamous Cancer of Nasal Cavity / Paranasal Sinuses (I-NAPA)RecruitingNCT05027633Phase 2
- Neoadjuvant Pembrolizumab in Cutaneous Squamous Cell CarcinomaRecruitingNCT05025813Phase 2
- NeoAdjuvant Pembrolizumab and STEreotactic Radiotherapy Prior to Nephrectomy for Renal Cell CarcinomaRecruitingNCT05024318Phase 2
- Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid TumorsRecruitingNCT05024214Phase 1/2
- A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for Rectal Cancer.RecruitingNCT05024097Phase 2
- Correlation of Clinical Response to Pathologic Response in Patients With Early Breast CancerRecruitingNCT05020860Phase 2
- Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma, TACOS StudyRecruitingNCT05019703Phase 2
- A Phase 3 Study to Evaluate Surufatinib Plus Toripalimab in the Treatment of Advanced Neuroendocrine CarcinomaRecruitingNCT05015621Phase 3
- Camrelizumab and Chemotherapy Combined With Endoscopic Surgery for Recurrent Nasopharyngeal CarcinomaRecruitingNCT05011227Phase 2
- Lenvatinib Plus Sintilimab in Patients with Immune Checkpoint Inhibitor Previously Treated Advanced Liver CancerRecruitingNCT05010681Phase 2
- Sintilimab With Pemigatinib in Patients With PD-L1-positive and FGFR Mutated Advanced Non-small Cell Lung CancerRecruitingNCT05004974Phase 2
- Chemotherapy With or Without Immunotherapy for Peritoneal MesotheliomaRecruitingNCT05001880Phase 2
- Neoadjuvant Sintilimab in Combination With Carboplatin and Nab-paclitaxel in Untreated Salivary Gland Malignant NeoplasmsRecruitingNCT05000892Phase 2
- Atezolizumab Plus Tivozanib in Immunologically Cold Tumor TypesRecruitingNCT05000294Phase 1/2
- AB122 Platform StudyRecruitingNCT04999761Phase 1
- First in Human, Dose Escalation Study of AN4005RecruitingNCT04999384Phase 1
- Study of Adjuvant Chemotherapy With or Without PD-1 Inhibitors and Chemoradiotherapy in Resected pN3 Gastric (G) or GEJ AdenocarcinomaRecruitingNCT04997837Phase 3
- Atezolizumab Versus Placebo for the Adjuvant Treatment of Malignant Pleural Mesothelioma (Atezomeso)RecruitingNCT04996017Phase 3
- HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced SarcomaRecruitingNCT04995003Phase 1
- Sintilimab in Combination With Chidamide in Newly Diagnosed ENKTCLRecruitingNCT04994210Phase 2
- Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With SurgeryRecruitingNCT04991025Phase 2
- Study of Palliative Radiation Combined with Pembrolizumab in Unresectable Metastatic Stage IV Breast CancerRecruitingNCT04990921Phase 2
- Trial of Cemiplimab, or Cemip-Chemo Followed by Biomarker-guided Treatment for Pts w/HPV H&N CaRecruitingNCT04988074Phase 2
- A Trial of Pamiparib With Tislelizumab in Patients With Advanced Tumours With Homologous Recombination Repair DefectsRecruitingNCT04985721Phase 2
- A Phase Ib/II Study of GT90001 Combined With KN046 in Solid TumorsRecruitingNCT04984668Phase 1/2
- Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney CancerRecruitingNCT04981509Phase 2
- Fluzoparib and Camrelizumab in Treating Patients With R/M NPC That Progressed After First-line ChemotherapyRecruitingNCT04978012Phase 2
- GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid TumorsRecruitingNCT04977453Phase 1/2
- Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent GlioblastomaRecruitingNCT04977375Phase 1/2
- Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell CarcinomaRecruitingNCT04975152Phase 1
- Neoadjuvant Immunotherapy Plus CRT Versus Neoadjuvant CRT for Locally Advanced Resectable ESCCRecruitingNCT04973306Phase 2/3
- Preoperative Sintilimab Combined With Bevacizumab and Chemotherapy for Resectable Non-Small Cell Lung CancerRecruitingNCT04973293Not applicable
- Using ctDNA to Determine Therapies for Lung CancerRecruitingNCT04966663Phase 2
- Orelabrutinib, Sintilimab and Temozolomide in Relapsed or Refractory Central Nervous System LymphomaRecruitingNCT04961515Phase 2
- A Study of Sintilimab in Combination With Axitinib in Advanced Renal Cell CancerNot yet recruitingNCT04958473Phase 2
- TACE Combined with Tislelizumab in Patients with Advanced Intrahepatic CholangiocarcinomaRecruitingNCT04954781Phase 2
- Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate CancerRecruitingNCT04946370Phase 1/2
- BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and NivolumabRecruitingNCT04933903Phase 2
- Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 3)RecruitingNCT04932187Phase 1
- SRT in Combination With Pembrolizumab in Patients With Recurrent Prostate Cancer After Radical ProstatectomyRecruitingNCT04931979Phase 2
- A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)RecruitingNCT04929223Phase 1
- DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell LymphomaRecruitingNCT04920617Phase 2
- APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant EffusionRecruitingNCT04919629Phase 2
- Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung CancerRecruitingNCT04919382Phase 2
- Adjuvant Chemotherapy and Anti-PD-1 Antibody in Patients With Stage IIIC2-IVB Cervical CancerRecruitingNCT04918628Phase 2
- Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian CancerRecruitingNCT04918186Phase 2
- A Phase Ⅱ Study of Anlotinib Combined With Tislelizumab and AT in the Neoadjuvant Treatment of Triple-negative Breast CancerRecruitingNCT04914390Phase 2
- Relatlimab With Nivolumab and 5-Azacytidine for the Treatment of AMLRecruitingNCT04913922Phase 2
- Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRCRecruitingNCT04912765Phase 2
- Dose Tapering and Early Discontinuation to InCreAse cosT-effectIveness Of Immunotherapy for NSCLCRecruitingNCT04909684Phase 3
- Study of Camrelizumab Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)Not yet recruitingNCT04907344Phase 2/3
- Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIVRecruitingNCT04902443Phase 1
- Olaptesed With Pembrolizumab and Nanoliposomal Irinotecan or Gemcitabine/Nab-Paclitaxel in MSS Pancreatic CancerNot yet recruitingNCT04901741Phase 2
- Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 TherapyRecruitingNCT04892953Phase 2
- ENVAFOLIMAB Single-agent Treatment in Patients With Advanced Solid TumorsRecruitingNCT04891198Phase 2
- HIPEC Combined With Camrelizumab, Paclitaxel and S-1 for Conversion Therapy in Patients With Advanced Gastric Cancer With Peritoneal MetastasisNot yet recruitingNCT04889768Not applicable
- A Trial of Camrelizumab Combined With Microwave Ablation and Chemotherapy in the Treatment of Colorectal Cancer Liver Metastasis/Pulmonary MetastasisNot yet recruitingNCT04888806Phase 2